Interaction of a single drug with multiple targets through ''polypharmacology'' is increasingly recognized as necessary for treatment of complex diseases, such as schizophrenia. G protein-coupled receptors (GPCRs) are major medicinal targets, and understanding the structural basis of both GPCR drug selectivity and promiscuity could provide novel avenues for drug development.
With few exceptions, human disease is multifactorial, and the design of effective therapeutics requires the weaving of chemical threads to address barriers of drug delivery, distribution, and elimination while balancing target selectivity and activity to achieve therapeutic efficacy and limit undesirable side effects. Most drug discovery programs have addressed the latter by prioritizing high target selectivity. However, for many diseases-including neuropsychiatric and metabolic disorders-monotherapy (i.e., selectively targeting a single receptor) can provide only limited benefit. This arises both from the complexity and redundancy in key physiological responses and the polygenic nature of disease. For example, the most effective antipsychotics are those that target multiple G protein-coupled receptors (GPCRs), indicating that polypharmacology is required for superior efficacy (Roth et al., 2004) . Nonetheless, rational exploitation of chemical promiscuity requires fine structural understanding of interactions that govern both binding promiscuity and selectivity. The recent study by Peng et al. (2018) provides an important advance in this endeavor by combining the solution of novel crystal structures of the therapeutically important serotonin 5-hydroxytryptamine (5HT) 2C GPCR bound to selective (ritanserin) and promiscuous (ergotamine) ligands with detailed structural, pharmacological, and cheminformatic analyses. This multipronged approach yields new insights into the structural basis of selectivity of 5HT 2 receptors and the broad interaction of ergotamine and related compounds with diverse subtypes of GPCRs.
GPCRs are the most abundant cell surface proteins and play critical roles in virtually all key biological processes. These receptors are subclassified based on evolutionary and sequence conservation, with class A GPCRs accounting for the vast majority, and best exploited therapeutically. A key realization from drug discovery programs targeting class A GPCRs is that particular chemical substructures are over-represented, leading to the identification of ''privileged'' structures that, in turn, has driven development of target-focused libraries to exploit such scaffolds. This privileged binding is thought to arise from the common threedimensional fold of target proteins and evolutionary conservation in sequence among related proteins. In most cases, such broad interactions occur with relatively low affinity, requiring further chemical elaboration to improve and tune selective affinity for a given target. Ergotamine is an exception to this pattern-having nanomolar to subnanomolar affinity for over 20 class A GPCRs-and thus represents an excellent test case for understanding privileged scaffold promiscuity. While the GPCRs exhibiting high ergotamine affinity are principally of the subclade of aminergic receptors, weak interactions were also observed with less related GPCRs, including the d opioid receptor. Comparison of the pose of ergotamine in complexes with the 5HT 2C , 5HT 1B , and 5HT 2B receptors revealed that the ergoline core is bound by nine receptor residues that form polar and tight packing interactions, and these amino acids are highly conserved between receptors exhibiting high affinity for ergotamine. An additional key interaction between a conserved, small aliphatic residue in extracellular loop 2 and the cyclic tripeptide moiety of ergotamine was also observed (Peng et al., 2018) .
Of course, the ability to bind a given receptor is only part of the functionality required for polypharmacological ligands, and rational design must also incorporate an understanding of the different modes of activation and regulation for each receptor able to bind a promiscuous ligand. This fact is underscored by the work of Peng et al. (2018) , where ergotamine displayed different spectra of signaling efficacy for different GPCR classes and subtypes where it has high affinity, even when only examined in assays of canonical G protein activation and arrestin recruitment. More generally, there is still an enormous gap between our capacity to predict compound binding versus pharmacological behaviors such as inverse, partial, or biased agonism, or allosteric modulation. Our ability to do this will require greater diversity in high-resolution structures-even of the same receptorthat are bound to ligands of distinct pharmacology, as well as in complex with different transducer and/or regulator proteins. Encouragingly, significant strides are being made in this space through solution of more high-resolution structures and examination of specific ligand-receptor interactions that may be linked to distinct signaling outcomes (also highlighted by Peng et al., 2018) , as well as studies combining broad pharmacological fingerprinting with detailed computational, mutational, and pharmacological analyses (e.g., Schö negge et al., 2017).
In contrast to ergotamine, ritanserin provides an example of an elaborated compound with high selectivity for 5HT 2 receptors, yet it contains the privileged substructure 4-benzylidenepiperidine, which is common to many GPCR-active compounds ( Figure 1) . As illustrated by Peng et al. (2018) , compounds with this substructure display a diverse spectrum of receptor interactions, ranging from those that are highly promiscuous (e.g., clozapine, cinnarizine, or cyproheptadine) to those that are selective (e.g., ritanserin, CHEMBL1914849, or CHEMBL330291). The 5HT 2C -ritanserin structure thus enables an atomic-level rationalization of how the privileged 4-benzylidenepiperidine scaffold can be elaborated upon to drive binding selectivity, as well as the likely basis for broader receptor interactions of ligands, such as clozapine (Figure 1 ). Of note, clozapine is a therapeutically effective antipsychotic via its polypharmacology; however, its clinical utility is limited by extensive side effects that are driven by a subset of undesirable receptor interactions; these are likely a combination of ''within-target'' effects, as well as a consequence of the breadth of GPCRs targeted by this compound. In addition, the GPCR structural biology revolution has spurred advances in bioinformatics and chemogenomics to identify and predict structural conservation in positioning of amino acids that likely contribute to small molecule binding. One such approach, termed COINpocket (Ngo et al., 2017) , has been proposed as a method for identification of ligands for orphan receptors, while the broader adoption of ligand fingerprinting, receptor clustering, and network analyses (Piscitelli et al., 2015; Roth et al., 2017; Venkatakrishnan et al., 2013) holds promise for identifying potential compounds exhibiting polypharmacology.
Collectively, these findings highlight an ongoing hurdle to rationally exploiting polypharmacology: namely, can we identify not only the required binding selectivity/ promiscuity profile, but also the intrinsic efficacy and functional selectivity profile, for each targeted receptor that is required to optimally treat the clinical indication in a manner that is disease-context specific? To date, this is not well studied, although it is pleasing to see recent work explicitly aiming to link in vitro binding and functional fingerprints of different classes of molecules to optimal preclinical efficacy using in vivo models of disease (e.g., Bradley et al., 2017; Schmid et al., 2017) . At the end of the day, our eventual success will be determined by a balance of our (albeit incomplete) understanding of disease and our ability to chemically manipulate both receptor interaction profiles and desired pharmacodynamics properties. Studies like that of Peng et al. (2018) provide an important step in the right direction. Privileged chemical scaffolds can interact with a broad array of receptors. Understanding atomic details of receptor-ligand interaction can provide an understanding of the chemical vectors that can be exploited to maintain or limit receptor interaction, providing rational polypharmacology. The illustrated example shows the privileged substructure, 4-benzylidenepiperidine, and the key transmembrane (TM) domains of class A GPCRs with which it interacts. The inset indicates the mostly conserved amino acids that bind this substructure. Elaboration of privileged scaffolds along certain vectors (R 1 , R 2 , etc.) can be exploited to build in selectivity (e.g., ritanserin, which is highly selective for 5HT 2 receptors) or avoided to ensure promiscuity in target binding through polypharmacology (e.g., clozapine). The retention of polypharmacology in individual ligands provides potential advantage over combination therapies due to the complexities of balancing pharmacokinetics and side-effect profiles across multiple compounds, and this is particularly true for CNS-targeted drugs.
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